|

Real-life Clinical Outcomes of Direct Oral Anticoagulants (MACACOD)

RECRUITINGSponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Actively Recruiting
SponsorFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Started2019-07-29
Est. completion2024-08
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04042155

Summary

MACACOD is a clinical record in the usual clinical practice of direct oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). Design: single-center, observational, prospective, uncontrolled study of anticoagulated patients with any direct oral anticoagulant (DOAC) with atrial fibrillation or venous thromboembolism to determine the incidence of serious complications (thromboembolic or hemorrhagic) in real life

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

· Patients older than 18 years.

* With atrial fibrillation or recurrent venous thrombosis.
* In chronic treatment with any DOAC type drug.
* Patients who sign the informed consent

Exclusion Criteria:

* Patients who do not guarantee collaboration.
* Patients with advanced cognitive impairment and not supervised.
* Patients with alcoholism.
* Patients with psychiatric disorder and not supervised

Conditions3

Atrial FibrillationHeart DiseaseRecurrent Venous Thromboembolism

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.